Skip to main content

APPFOLIO INC

For the period ended Dec 31, 2023. Filed Feb 1, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 1, 2024

APPF$229.49-0.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Consolidated Statements of Operations

(in thousands, except per share amounts)

Year Ended December 31,
202320222021
Revenue$620,445$471,883$359,370
Costs and operating expenses:
Cost of revenue (exclusive of depreciation and amortization)(1)238,076191,826143,944
Sales and marketing(1)107,602107,39873,200
Research and product development(1)151,364111,11865,980
General and administrative(1)93,452100,79257,279
Depreciation and amortization28,98833,11930,845
Total costs and operating expenses619,482544,253371,248
Income (loss) from operations963(72,370)(11,878)
Other income (loss), net34,46913,111
Interest income, net7,0311,184501
Income (loss) before provision for income taxes7,997(66,717)1,734
Provision for income taxes5,2951,402706
Net income (loss)$2,702$(68,119)$1,028
Net income (loss) per common share:
Basic$0.08$(1.95)$0.03
Diluted$0.07$(1.95)$0.03
Weighted average common shares outstanding:
Basic35,62935,01034,578
Diluted36,41735,01035,701

(1) Includes stock-based compensation expense as follows:

Year Ended December 31,
202320222021
Stock-based compensation expense included in costs and operating expenses:
Cost of revenue (exclusive of depreciation and amortization)$3,703$2,640$2,024
Sales and marketing5,9838,6812,329
Research and product development20,97416,0305,457
General and administrative21,70413,5845,531
Total stock-based compensation expense$52,364$40,935$15,341
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.